At a glance
- Originator Pfizer
- Class Antibacterials; Fluoroquinolones; Naphthyridines; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 21 Jan 2008 Discontinued - Phase-I for Bacterial infections in USA (unspecified route)
- 15 Jan 2004 No development reported - Phase-I for Bacterial infections in USA (unspecified route)
- 21 Jun 2000 Warner-Lambert has merged with Pfizer